Epigenetic alteration contributes to the transcriptional reprogramming in T-cell prolymphocytic leukemia

Shulan Tian(Mayo Clinic), Wei Ding(Mayo Clinic)

Scientific Reports

April 15, 2021

10.1038/s41598-021-87890-9

Cited by 3

Related Papers

Platelet-derived growth factor (PDGF)–PDGF receptor interaction activates bone marrow–derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch

|Blood|2010|148

Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma

|Neuro-Oncology|2021|81

Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain Barrier

|Molecular Cancer Therapeutics|2018|40

A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia

|Blood Advances|2024|19

Data from Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain Barrier

|Unknown|2023|0